Browse CD5L

Summary
SymbolCD5L
NameCD5 molecule-like
Aliases Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted Cytoplasm Note=Secreted by macrophages and circulates in the blood (PubMed:24223991, PubMed:24804991). Transported in the cytoplasm via CD36-mediated endocytosis (By similarity).
Domain PF00530 Scavenger receptor cysteine-rich domain
Function

Secreted protein that acts as a key regulator of lipid synthesis: mainly expressed by macrophages in lymphoid and inflammed tissues and regulates mechanisms in inflammatory responses, such as infection or atherosclerosis. Able to inhibit lipid droplet size in adipocytes. Following incorporation into mature adipocytes via CD36-mediated endocytosis, associates with cytosolic FASN, inhibiting fatty acid synthase activity and leading to lipolysis, the degradation of triacylglycerols into glycerol and free fatty acids (FFA). CD5L-induced lipolysis occurs with progression of obesity: participates in obesity-associated inflammation following recruitment of inflammatory macrophages into adipose tissues, a cause of insulin resistance and obesity-related metabolic disease. Regulation of intracellular lipids mediated by CD5L has a direct effect on transcription regulation mediated by nuclear receptors ROR-gamma (RORC). Acts as a key regulator of metabolic switch in T-helper Th17 cells. Regulates the expression of pro-inflammatory genes in Th17 cells by altering the lipid content and limiting synthesis of cholesterol ligand of RORC, the master transcription factor of Th17-cell differentiation. CD5L is mainly present in non-pathogenic Th17 cells, where it decreases the content of polyunsaturated fatty acyls (PUFA), affecting two metabolic proteins MSMO1 and CYP51A1, which synthesize ligands of RORC, limiting RORC activity and expression of pro-inflammatory genes. Participates in obesity-associated autoimmunity via its association with IgM, interfering with the binding of IgM to Fcalpha/mu receptor and enhancing the development of long-lived plasma cells that produce high-affinity IgG autoantibodies (By similarity). Also acts as an inhibitor of apoptosis in macrophages: promotes macrophage survival from the apoptotic effects of oxidized lipids in case of atherosclerosis (PubMed:24295828). Involved in early response to microbial infection against various pathogens by acting as a pattern recognition receptor and by promoting autophagy (PubMed:16030018, PubMed:24223991, PubMed:24583716, PubMed:25713983).

> Gene Ontology
 
Biological Process GO:0006898 receptor-mediated endocytosis
GO:0006968 cellular defense response
Molecular Function GO:0005044 scavenger receptor activity
GO:0038024 cargo receptor activity
Cellular Component GO:0072562 blood microparticle
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolCD5L
NameCD5 molecule-like
Aliases Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD5L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD5L and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21697282Lung AdenocarcinomaInhibit immunityApi6/AI M/SpĪ±/CD5L overexpression in alveolar type II epithelial cells induces spontaneous lung adenocarcinoma. Here, we report that Api6 promotes malignant transformation by limiting lung epithelial cell apoptosis and promoting immune escape. Api6 overexpression inhibited apoptosis and activated oncogenic signaling in AT II lung epithelial cells, inducing emphysema and adenocarcinoma. In addition, Api6 overexpression in AT II cells increased the concentrations of proinflammatory cytokines/chemokines in bronchoalveolar lavage fluid and serum, promoting expansion of myeloid-derived suppressor cells (MDSC) in lung and blood but not in bone marrow or spleen.
Summary
SymbolCD5L
NameCD5 molecule-like
Aliases Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD5L in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD5L
NameCD5 molecule-like
Aliases Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD5L in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3160.602
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0690.943
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4820.563
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.2070.183
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9030.499
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.5940.29
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.670.538
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0330.497
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5210.752
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.380.736
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4210.775
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5420.0345
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD5L in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.5010.50.135
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.2018.20.274
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD5L
NameCD5 molecule-like
Aliases Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD5L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD5L
NameCD5 molecule-like
Aliases Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD5L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD5L.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD5L
NameCD5 molecule-like
Aliases Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD5L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD5L
NameCD5 molecule-like
Aliases Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD5L expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD5L
NameCD5 molecule-like
Aliases Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD5L and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD5L
NameCD5 molecule-like
Aliases Spalpha; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); PRO229; SP ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD5L collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.